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Abrogation of glomerular injury in nephrotoxic nephritis by continuous
infusion of interleukin-6. Interleukin-6 (IL-6) has been reported to have
pro- and anti-inflammatory effects. It has also been shown to cause
mesangial cell proliferation in vitro and has been suggested as a mediator
of injury in proliferative nephritis. We have assessed the effects of
continuous infusion of human recombinant (hr) IL-6, by osmotic
minipump, on the degree of glomerular injury, and on glomerular and
interstitial cell proliferation, in the accelerated autologous phase of
nephrotoxic nephritis. Two groups of rats were pre-immunized with 1 mg
of normal rabbit IgG in Freund's complete adjuvant. One week later,
nephritis was induced by an intravenous injection of 1 ml of rabbit
nephrotoxic serum. One day before the induction of nephritis, group 1
(N = 9) was subcutaneously implanted with osmotic minipumps filled with
50 rg (200 pA) of IL-6 (equivalent to a dose of 6 pg/day), while in group
2 (N = 11) the minipumps were filled with 200 jtl of normal saline. In
group 3 (N = 6) normal rats were infused with 50 irg of IL-6 alone. The
rats were killed seven days after implantation of minipumps. The admin-
istered hrIL-6 was detectable in the circulation within the pathophysio-
logical range, and induced a hepatic acute phase response, as assessed by
a2-macroglobulin levels. Continuous treatment with IL-6 resulted in a
significant reduction in albuminuria (from 195 37 mg/20 hr to 60 15
mg/20 hr on day 1, and from 494 52 mg/20 hr to 238 30 mg/20 hr on
day 7, p < 0.002) and in the prevalence of glomerular capillary thrombosis
(from 19 3% to 5 1%, P < 0.002). There was also a reduction in
macrophage infiltration (ED1 +ve cells from 524 34 to 466 14 per 50
glomeruli, P < 0.02) and activation (ED3+ve cells from 106 13 to 42
5 per 50 glomeruli, P < 0.002). Immunohistology showed fewer interstitial
Ia+ve cells (0X3 and 0X4) in the IL-6 treated group. Similar results were
obtained in a second set of experiments in which the IL-6 treatment was
extended until day 14. Kidney sections taken from nephritic rats infused
with IL-6 showed no increase in glomerular or interstitial cell proliferation
when stained with antibodies to proliferating cell nuclear antigen. There
was no difference in the deposition of rabbit lgG or rat IgG along the
glomerular basement membrane (GBM), and the titer of rat anti-rabbit
TgG was similar in the IL-6 and control treated rats. Infusion of IL-6 alone
in normal rats had no functional or pathological effects. In conclusion,
these results show that IT.-6 has powerful anti-inflammatory effects in a rat
model of anti-GBM nephritis, and does not induce mesangial cell prolif-
eration in vivO.
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Considerable controversy surrounds the role of interleukin-6
(IL-6) in the pathogenesis of proliferative glomerulonephritis.
Expression of IL-6 is increased in many patients with mesangial
proliferative glomerulonephritis [1], as well as in rodents with
experimental analogues [21. The intensity of expression has been
reported to correlate with the severity of injury [3, 4]. Transgenic
mice overexpressing IL-6 [5, 6] or the closely related cytokine
leukemia inhibitory factor (LIF) develop glomerular disease,
adding weight to the idea that IL-6 is pathogenic. However, these
mice have many other immunological abnormalities including
very high circulating IgG concentrations, that could be responsi-
ble for the glomerular disease. The justification for a pathogenic
role for IL-6 in nephritis is based on reports that IL-6 induces
mesangial cell proliferation in vitro [2, 3]. However, more recent
studies suggest that IL-6 either has no effect on mesangial cell
proliferation [7, 8], or inhibits it [9]. Furthermore, Matsell, Gaber
and Malik [10] demonstrated that exposure of serum stimulated
mesangial cells to IL-6 resulted in a dose-dependent inhibition of
both mitogenesis and proliferation mediated, in part, by endoge-
nous prostaglandin F2 (PGE2) synthesis. The different results
cannot be explained by species differences, and the conclusion
must be that IL-6 is not a powerful mesangial cell mitogen.
Interleukin-6 could influence injury in nephritis in other ways. It
has definite but partially characterized effects on macrophages,
which decrease their inflammatory properties [11, 12]. Thus, IL-6
reduces synthesis of interleukin-1 (IL-i) and tumor necrosis
factor-a (TNF) by macrophages [13, 14], and stimulates them to
release their antagonists, including IL-i receptor antagonist (IL-
Ira) and soluble TNF receptor [15, 16]. This suggests that IL-6
might have a protective role in nephritis, and our previous studies
in the heterologous phase of nephrotoxic nephritis (NTN) dem-
onstrate that this is the case. IL-6 reduced the expression of IL-i
and TNF within the inflamed glomerulus, and partially abrogated
glomerular injury [17].
The purpose of the present study was to ascertain whether a
continuous infusion of IL-6 could influence the more severe and
persistent inflammation in the telescoped model of nephrotoxic
nephritis (NTN). This model was chosen because the injury is
dependent on macrophage infiltration [18, 19] and activation [20],
and on synthesis of IL-i [21, 22] and TNF [23, 24]. The results
show that IL-6, administered in doses sufficient to increase plasma
concentrations into the pathophysiological range, markedly atten-
uates injury in this model without exaggerating glomerular cell
1313
1314 Karkar et al: Continuous infusion of IL-6 ameliorates NTN
proliferation. These experiments establish the principle that sys-
temic administration of an anti-inflammatory cytokine can be
used to manipulate glomerular inflammation.
METHODS
Animals
Male Sprague-Dawley rats weighing 180 to 200 g were used in
all the experiments. They were housed individually in metabolism
cages for 20-hour urine collections and had free access to food
and water.
Reagents
Rabbit serum containing high titers of antibodies to rat glomer-
ular basement membrane (GBM) was prepared with special care
to avoid contamination with endotoxin as previously described
[251. The resulting nephrotoxic serum (NTS) was tested for
contamination with LPS by Limulus amoebocyte lysate assay, and
the final concentration was always less than 5 pg/ml of NTS.
Normal rabbit IgG and Freund's complete adjuvant (FCA) were
purchased from Sigma (Sigma Chemical Co., St. Louis, MO,
USA). A stock solution of 2.5 mg/ml of LPS (LPS, Salmonella
lyphimurium; Sigma Chemical) was prepared and stored at 4°C
until required. Human recombinant interleukin-6 (hrIL-6) was
prepared at the Glaxo Institute of Molecular Biology (Geneva,
Switzerland). It has a specific biological activity of 2.8 X 1010
U/mg and is active at a concentration of 0.1 p, as determined by
the hybridoma growth activity of 7TDI cells [26]. It was contam-
inated with less than 5 pg/mI of endotoxin (Limulus test). The
cDNA probe for rat IL-i f3 was kindly provided by Dr. Alan Shaw
(Biogen, Geneva, Switzerland), and the cDNA probe for rat
IL-Ira was prepared locally by the PCR technique [27]. The
cDNA probe for rat MCP-1 was a 665 bp insert subcloned into
pBLUEScript plasmid [28]. The cDNA probe for human tubulin
kal was a 1.6 kb insert subcloned into pSP64 plasmid, which was
used as a control to cross hybridize to rat mRNA [29].
Implantation of the minipumps
Alzet model 2001 osmotic minipumps (Alzet, Palo Alto, CA,
USA) have a volume capacity of 200 j.tl that is delivered at a rate
of I pd/hr for one week. Except where stated otherwise, the
minipumps were filled with either 50 tg (200 jil) of IL-6 (equiv-
alent to a dose of 6 pg/day) in the experimental groups, or with
the vehicle normal saline (200 d) in the control group. They were
implanted subcutaneously by a small incision on the back of rats
under light ether anesthesia 24 hours before induction of nephri-
tis. The minipumps were replaced after seven days in the 14 day
experiments.
Induction of nephrotoxic nephritis
The accelerated autologous phase of nephrotoxic nephritis was
induced by a single intravenous injection of 1 ml of NTS one week
after immunizing rats with 1 mg of normal rabbit IgG in FCA
subcutaneously. The severity of nephritis was assessed both
functionally and morphologically using previously described
methods [17, 30]: urinary albumin excretion in mg per 20 hours
was measured at standard times throughout the experiments, the
percentage of glomeruli with at least one capillary thrombus was
estimated after scanning 50 consecutive glomeruli, and the num-
ber of inflammatory cells (both neutrophils and macrophages)
infiltrating the glomeruli was counted. The assessment of glomer-
ular injury was conducted in separate experiments performed at
one and two weeks after the implantation of minipumps and
administration of NTS.
Histology and immunohistochemistry
Tissue was fixed in neutral buffered formal saline and embed-
ded in paraffin. Sections were stained with hematoxylin and eosin,
and periodic acid-Schiff. Immunofluorescence staining for rabbit
anti-rat IgG and rat anti-rabbit IgG along rat GBM was per-
formed on frozen sections taken from IL-fl treated and control
groups [31]. Immunoperoxidase staining was performed for the
detection of glomerular macrophage infiltration and activation
using monoclonal mouse anti-rat antibodies (ED1 and ED3,
respectively; Serotec, Oxford, UK). The state of macrophage
activation was also detected by mouse monoclonal antibodies to
rat Ia antigens 0X3 and 0X4 (Seralab, Crawley Down, UK) [32].
The same technique was used to study glomerular and interstitial
cell proliferation, using a monoclonal mouse anti-human prolif-
erating cell nuclear antigen (PCNA) antibody (Serotec), which
cross reacts with rat tissues [33].
The immunoperoxidase technique was performed as described
previously [17]. Briefly, four micron-thick frozen sections were
prepared from rat kidneys from different experimental groups.
These were mounted on poly-L-lysine-coated glass slides, air
dried for about one hour, and then fixed for 10 minutes in cold
acetone. The slides were rehydrated in phosphate buffered saline
(PBS), treated for 30 minutes with hydrogen peroxide in PBS to
block endogenous peroxidase activity, and washed again with
PBS. Next, they were treated with a 1:50 dilution of blocking
normal sheep serum for 30 minutes and then exposed to different
dilutions of either ED1 (1:2500), ED3 (1:500), 0X3, 0X4 (1:50),
or PCNA (1:50) or similar dilutions of control mouse monoclonal
antibodies. After overnight incubation in a humid chamber at 4°C,
the slides were rinsed and washed three times with PBS, overlaid
with peroxidase-conjugated secondary polyclonal sheep anti-
mouse antibody (dilution 1:100; Amersham International, UK),
and incubated for one hour, followed by three additional rinses
and washes with PBS. At this point, sections were overlaid with
substrate DAB (3,3'-Diaminobenzedine tetrahydrochioride dihy-
drate, 97%; Aldrich Chemical Co., Gillingham, UK) with hydro-
gen peroxide in PBS and incubated for 15 minutes at room
temperature to allow color development. Harris's hematoxylin
was used as a counterstain. Glomerular macrophage infiltration,
the number of activated macrophages, and proliferating cells were
counted per 50 glomeruli in section.
Assessment of rat immune response to rabbit IgG
Blood samples were collected, by tail vein bleed, on alternate
days following the induction of nephritis. Levels of anti-rabbit IgG
antibodies were measured by ELISA [34]. The results were
expressed in ELISA units, defined as the ratio of the optical
density (OD) with the test serum to that with pooled non-immune
rat sera.
Measurement of serum IL-6 concentrations
The blood samples collected on alternate days following the
induction of nephritis were also used to detect the concentrations
of administered hrIL-6 in rat serum. IL-6 was measured in pg/mI
using a Quantikine ELISA kit (R&D Systems, Abingdon, UK).
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Northern blotting
In these studies, the kidneys were removed from rats killed
seven days after the minipumps were implanted. Northern anal-
ysis was performed as previously described [8]. Briefly, kidney
tissue was collected for mRNA studies after the lower pole of the
left kidney was removed for histology while the rats were under
ether anesthesia. Before removal, the kidneys were perfused in
vivo with 50 ml of PBS at room temperature followed by 10 ml of
ice cold PBS. Glomeruli were purified from the rest of the renal
tissues by a standard sieving technique (using consecutive 250 ,
150 t, and 63 .t sieves) with ice cold PBS. Purified glomeruli were
immediately homogenised (Ika Ultra-Turrax T25; Janke and
Kunkal, Staufen, Sweden) at 24000 rpm in 4 M guanidinium
thiocyanate solution. Total RNA was purified from the homoge-
nate using the caesium chloride gradient ultracentrifugation
method [35]. Equal amounts of total glomerular RNA were
electrophoresed on a 3.2% formaldehyde, lx MOP, 1% agarose
gel and transferred to GeneScreen plus°° (New England Nuclear,
Boston, MA, USA), by capillary blot using 10 x SSC solution (1 x
SSC = 15 mi trisodium citrate, 150 m sodium chloride). Filters
were prehybridized in 50% formamide, 1% SDS, 10% dextran
sulphate, 1 M NaCI and 200 g/ml denatured salmon testes DNA
(Sigma) overnight at 42°C. Complementary DNA probes were
radiolabeled with 32P-CTP using Klenow DNA polymerase (Sam-
brook, Fritsch, Maniatis). Filters were hybridized in the same
prehybridization buffer at 42°C with radiolabeled probe overnight.
They were washed twice in 1% SDS + I X SSC solution at room
temperature for five minutes, twice at 42°C for 30 minutes and
twice in 1% SDS + 0.1 X SSC solution for another 30 minutes at
the same temperature. Some filters were washed further in 1%
SDS + 0.01 to 0.1 x SSC solution to reduce background
radioactivity. Washed filters were exposed to X-OMAT Kodak
film with an intensifier screen at room temperature or —70°C for
various durations up to 14 days. Multiple exposure times were
used to ensure that optimally exposed films were available for
densitometry. Filters were stripped of radioactivity by washing in
boiling 0.1% SDS and 0.1 x SSC solution before the next
hybridization. The degree of hybridization was assessed by densi-
tometric scanning (Chromoscan 3, Joyce Loebl) of suitable auto-
radiographs. Any difference in RNA loading in each lane was
corrected by normalisation to the tubulin hybridization.
Assessment of the hepatic acute phase response
The hepatic acute phase response was assessed functionally by
measurement of plasma alpha 2-macroglobulin (a2m) concentra-
tion as previously described [30].
Measurement of serum corticosterone
The blood samples that were collected on days 0, 1, 3 and 7
following the implantation of minipumps were used to measure
endogenous cortieosterone concentrations in rat serum. Cortico-
sterone was measured in ng/ml using a Biotrack radioimmunoas-
say kit that is specific for rat corticosterone (Amersham Life
Science, UK).
Statistical analysis
The data are presented as means together with standard errors
(sv). The probabilities that differences between the groups were
significant were calculated using Wilcoxon rank sum test.
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Fig. 1. Effectiveness of hrIL-6 in inducing acute phase response in rats,
manifested by changes in plasma concentration of a2m following contin-
uous infusion, using subcutaneously implanted minipumps, of either 50
g IL-6 (U; N = 3) or 1 mg LPS (A; N = 3), which demonstrates a
comparable effect of both stimuli on plasma concentration of a2m. The
basal concentration of a2m in all rats was 192 18 Wml, which was not
statistically different from rats infused with normal saline (S; N = 3) or
rats implanted with empty minipumps (0; N 3). Abbreviations are:
hrTL-6, human recombinant interleukin-6; o2m, alpha 2-macroglobulin;
LPS, bacterial lipopolysaccharide; N, number of rats.
RESULTS
Detection and biological effectiveness of hrIL-6 in rats
The circulating concentration of administered hrIL-6 was stud-
ied in five groups of rats (N = 6 per group), with minipumps filled
with different doses of hrIL-6 (1, 2, 4, 8, and 50 gig) diluted in
normal saline. Blood samples were taken at the start of the
experiment and every other day thereafter. Human recombinant
IL-6 was detectable by ELISA in serum (10 to 120 pg/ml) of all the
rats treated with 50 j.tg hrIL-6 in 200 1d (equivalent to 6 j.g/day),
but was undetectable in the groups treated with lower doses. The
hrIL-6 was biologically active in vivo, as judged by serum concen-
trations of the acute phase hepatic protein cr2m. Treatment with
IL-6 increased c2m from the baseline of 192 18 j.g/ml to 2878
211 j.tg/ml on day 1, and 3389 289 pg/ml on day 3; levels
gradually declined to 1367 176 j.tg/ml on day 5 and 1080 154
j.tg!ml on day 7. The cs2m concentrations were even higher in rats
infused with LPS (5
.tg/hr) as a positive control, but the time
course was similar (5592 388 at day 1, 5457 876 at day 3,
2730 85 at day 5, and 1064 64 g/ml at day 7; Fig. 1). In
contrast, rats implanted with empty minipumps or infused with
normal saline had only a slight increase in a2m attributable to
operative stress (Fig. 1). Rats infused with IL-6 alone remained
healthy and showed no signs of distress, ruffling of fur or
significant change in weight when compared with the control
group. They did not develop albuminuria and had normal renal
morphology at autopsy. Thus, hrIL-6 in a dose of 50 .tg infused
over seven days increased serum IL-6 concentrations into the
pathophysiological range and caused an appropriate increase in
serum a2m concentration.
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Fig. 2. Effect of continuous infusion of hrIL-6 on urinary excretion of
albumin in accelerated autologous NTN. All rats were killed one week
after the implantation of minipumps. Urinary albumin excretion was
measured, by rocket immunoelectrophoresis, in all rats on a daily basis
(mg/20 hr), and showed a significant reduction in daily albuminuria in the
IL-6 treated group when compared with the control group (P < 0.002).
Infusion of IL-6 alone did not cause any albuminuria. Abbreviations are:
hrIL-6, human recombinant interleukin-6; NTN, nephrotoxic nephritis;
NTS, nephrotoxic serum; N, number of rats. Symbols are: (•) control +
NTS (N = 11); (•) IL-6 + NTS (N = 9); (0) IL-6 only (N = 6).
Effect of IL-6 infusion on glomerular injury in NTN
The effect of continuous infusion of IL-6 on glomerular injury
in NTN was studied in two groups of rats: Group 1 (9 rats) were
implanted with minipumps filled with 50 itg of IL-6, while Group
2 (11 rats) had minipumps filled with 200 1.d of normal saline. A
third group of normal rats (N =6) were infused with 50 j.tg of IL-6
alone. Nephritic rats infused continuously with IL-6 had signifi-
cantly less albuminuria than controls throughout the course of the
experiment (Fig. 2). The prevalence of glomerular capillary
thrombosis was also significantly less at seven days when the rats
were killed (from 19 3% of glomeruli to 5 1% of glomeruli,
P < 0.002), and there was a small but significant reduction in the
number of glomerular macrophages (ED1 +ve cells from 524 34
to 466 14 per 50 glomeruli, P < 0.02). There was a larger
reduction in the number of macrophages expressing the activation
marker sialoadhesin (ED3+ve cells from 106 13 to 42 5, P <
0.002, Wilcoxon rank sum test, Table 1), and also in the number
of Ia positive cells (0X3 and 0X4), which was less by 38% within
glomeruli and interstitium of the IL-6 treated group. Infusion of
IL-6 alone in normal rats had no functional or pathological effects.
A second experiment was conducted to examine the longer
term effect of IL-6 on NTN by replacing the minipumps on day 7
and extending the observations until day 14. The results confirmed
the effectiveness of IL-6 in reducing injury, and showed that
protection was maintained until day 14, when albuminuria (305
28 mg/20 hr in IL-6 treated rats vs. 619 77 mg/20 hr in controls,
P < 0.001) and glomerular capillary thrombosis (17 2% in
treated rats vs. 40 9% in controls, P < 0.002) were both
significantly reduced. Again, there were less glomerular macro-
phages in IL-6 treated rats (535 39 vs. 621 29 positive cells
per 50 glomeruli, P < 0.05), and fewer sialoadhesin expressing
macrophages (84 12 vs. 153 10 positive cells per 50 glomeruli,
P < 0.002). IL-6 treatment had no effect on glomerular neutrophil
infiltration, and the more prolonged infusion of IL-6 alone in
normal rats had no detectable effect on renal function or mor-
phology.
The administered rabbit anti-rat GBM antibody (nephrotoxic
serum) and rat anti-rabbit IgG were localized immunohistologi-
cally at a similar fluorescence intensity along rat GBM in both the
IL-6 treated and control groups. There was no significant differ-
ence in the titer of rat anti-rabbit IgG antibodies, as measured by
ELISA, between IL-6 treated rats and vehicle treated controls
over the two-week study period.
Effect of IL-6 infusion on cell proliferation
The effect of IL-6 on glomerular and interstitial cell prolifera-
tion was studied in kidney sections taken from rats killed at day 7
and day 14. Proliferating cell nuclear antigen (PCNA) positive
cells were not detected at day 7 in biopsies from any of the groups.
In contrast, sections obtained from nephritic rats killed at day 14
showed positive cells in the periphery of some glomeruli. There
were 7 I PCNA positive cells per 50 glomeruli in section in the
IL-6 treated group versus 10 3 in the normal saline treated
group. Examination of the interstitium showed 7 2 PCNA
positive cells per field in the IL-6 treated group versus 12 2 in
the normal saline treated group (Fig. 3). Infusion of IL-6 alone in
normal rats had no effect on glomerular or interstitial cell
proliferation when compared with normal rats infused with nor-
mal saline (Fig. 3). These data demonstrate that pathophysiolog-
ical levels of IL-6 do not cause glomerular or interstitial cell
proliferation in normal or nephritic rats.
Effect of IL-6 infusion on alpha 2-macroglobulin
Plasma concentration of a2m was increased in both groups of
nephritic rats and in those infused with IL-6 alone. At the start of
the experiment the baseline concentration in all rats was 187 16
jig/mI. Four hours later, cx2m increased to 1360 jig/mI in group 1,
1752 jig/ml in group 2, and 620 jig/mI in group 3. The concentra-
tion was higher in all groups on day 3: 8858 3883 jig/ml in group
1, 11840 1462 jig/mI in group 2, and 1625 268 j.tg/ml in group
3. The plasma concentration of cs2m continued to rise in both
groups of nephritic rats and reached higher levels on day 7:
10764 3471 j.tg/ml in group 1, 19410 2034 j.tg/ml in group 2;
and 715 167 jig/mI in group 3, respectively. These results show
that nephritic rats infused with normal saline had a vigorous acute
phase response to injury, while those treated with IL-6 had lower
concentrations of a2m (P < 0.05), presumably because they had a
smaller stimulus to an endogenous acute phase response because
glomerular injury was less.
Effect of IL-6 infusion on glomerular expression of IL-1, IL-
ira and MCP-1
Glomerular expression of IL-113, IL-ira and MCP-1 was inves-
tigated in two additional groups of rats with NTN killed seven
days after induction of nephritis. Northern analysis showed small
amounts of IL-1f3, IL-ira and MCP-1 mRNA in glomeruli,
without significant differences between the IL-6 and the control
treated groups at this time point (Fig. 4).
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Fig. 3. Effect of continuous infusion of IL-6 on glomerular and intersti-
tial cell proliferation, assessed by immunohistological staining with
antibodies to proliferating cell nuclear antigen (PCNA). Kidney sections
were taken from all rats which were killed 14 days after the implantation
of minipumps. Nephritic rats infused with IL-6 (N = 5) showed 7 1
versus 10 3 PCNA positive cells per 50 glomeruli (•) in section in
nephritic rats infused with normal saline (N = 5), and 7 2 and 12 2
PCNA positive cells per field (A) of interstitium, respectively. There was
no significant difference between the groups. Infusion of IL-6 alone (N =
2) had no effect on glomerular or interstitial cell proliferation when
compared with a control group of normal rats (N = 2) infuscd with normal
saline (6 I and 8 I positive cells in glomeruli and interstitium,
respectively).
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Fig. 4. Northern blot analysis of glomerular RNA isolated from rats
seven days after induction of nephrotoxic nephritis. During this period,
one group of rats (N = 6) was treated with continuous infusion of IL-fl by
osmotic minipumps, whereas nlinipumps in the control group (N = 6)
were filled with normal saline. Each sample of RNA was extracted from
glomeruli pooled from 3 rats of each group. A sample RNA was extracted
from the lung of an LPS injected rat and was included as a positive control
for hybridization. Aliquots of 25 jig of total RNA was loaded in each lane.
A) This Northern blot was sequentially hybridized with eDNA probes to
rat TL-i, rat IL-ira and tubulin (housekeeping gene). The positions of
ribosomal RNA bands (18S and 28S) are shown as size markers. (B) This
Northern blot shows other aliquots of the same RNA samples that were
sequentially hybridized with eDNA probes to rat MCP-i and tuhulin.
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Effect of IL-6 infusion on corticosterone levels
The baseline serum concentration of corticosterone was 203
31 ng/ml (N = 5). Infusion of IL-6 alone in normal rats (N = 5)
caused a significant increase in corticosterone concentration to
365 60 nglml on day 1 (P < 0.001) and to 546 66 ng/ml on day
3 (P < 0.001), hut fell to 317 34 ng/ml on day 7. However,
plasma corticosterone concentrations were similar in IL-6 (N 5)
and vehicle (N = 5) treated nephritic rats on day 1 (572 42
ng/ml vs. 580 41 nglml) and day 3 (508 65 ng/ml vs. 578 57
nglml). However, despite the fall in serum corticosterone concen-
trations on day 7, the IL-6 treated group maintained higher levels
(351 31 nglml) than the vehicle treated group (207 14 nglml,
P < 0.001). The findings exclude the possibility that the beneficial
effects of IL-6 are mediated solely through corticosteronc, at least
during the first few days after induction of nephritis.
DISCUSSION
Interleukin-6 is synthesized by mesangial cells and expressed in
inflamed glomeruli in experimental and human nephritis. IL-6 has
been reported to induce mesangial cell proliferation in vitro [1, 2],
and this led to the concept that it might mediate mesangial cell
injury and result in progressive glomerulonephritis [3, 4]. Our
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Table 1. Effect of continuous infusion of hrlL-6 on severity of glomerular injury in accelerated autologous phase of nephrotoxic nephritis
Albuminuria mg/20 hr
Day 3 Day 4 Day 5 Day7 % GCT ED1
Control + Ii 195 37 375 46 330 42 496 56 402 39 494 52 19 3 524 34 106 13 19410 2034
NTS a a a a a a a b a c
lL-6 + 9 60 15 118 19 152 23 221 35 228 43 238 30 5 1 466 14 42 5 10764 3471
NTS
Continuous infusion of IL-6 (50 rg per rat), by osmotic minipumps, caused a significant fall in daily albumin excretion when compared with the control
group. This was associated with a significant reduction in the prevalence of glomerular capillary thrombosis, and in glomerular macrophage infiltration
(ED1) and activation (ED3), as studied by immunohistological staining of kidney sections taken from all rats when killed on day 7 following induction
of nephritis and implantation of minipumps. Treatment with IL-6 resulted in lower plasma concentrations of a2m when compared with nephritic rats
infused with normal saline. Continuous infusion of IL-6 alone (N = 6) had no functional or morphological effects. Abbreviations are: hrIL-6, human
recombinant interleukin-6; NTS, nephrotoxic serum; a2m, alpha 2-macroglobulin; GCT, glomerular capillary thrombi; N, number of rats.
P < 0.002; bP < 0.02; C P < (1.05
results in vivo clearly show that increased serum concentrations of
IL-6 within the pathophysiological range do not increase glomer-
ular or interstitial cell proliferation in normal or inflamed kidneys
in nephrotoxic nephritis. On the contrary, it appears that contin-
uous infusion of IL-6 over a two week period has a tendency to
reduce the number of proliferating cells within the kidneys of rats
with acute nephritis. These findings are echoed by those of Eitner
et al [361 in the Thy 1.1 model of mesangial proliferative nephritis,
and by the absence of nephrotoxicity of pharmacological doses of
IL-6 in clinical studies [37]. They are also consistent with the in
vitro study by Ikeda et al [9] demonstrating that IL-6 inhibits the
proliferation of mesangial cells in a dose dependent manner.
Furthermore, Matsell, Gaber and Malik [101 have recently shown
that exposure of serum stimulated mesangial cells to IL-6 resulted
in a dose dependent inhibition of both mitogenesis and prolifer-
ation, an effect which was shown to be mediated, in part, by
endogenous prostaglandin E2 synthesis.
Interleukin-6 has a number of potentially anti-inflammatory
effects on macrophages, and here we have shown that it causes a
striking reduction in glomerular injury in an active model of
anti-GBM nephritis, assessed both by urinary albumin excretion
and the proportion of glomeruli with capillary thrombosis. The
beneficial effects were associated with a small reduction in gb-
merular macrophage infiltration, and evidence of reduced macro-
phage activation. The ability of IL-6 to deactivate macrophages in
vivo could be due to IL-6 induced synthesis of prostaglandins
(P0) [101. In vitro studies have shown that PGE can suppress
superoxide and IL-i and TNF production by activated macro-
phages [38]. Furthermore, administration of PGE in the same
model of nephritis (NTN) deactivated macrophages infiltrating
inflamed glomeruli, and ameliorated disease activity [39, 40].
Moreover, Riedy and Stewart [11] showed that IL-6 has potent
and specific inhibitory effects on macrophages. Taken together,
these findings and our previous results in the heterologous phase
of NTN [17], document the potent anti-inflammatory effects of
IL-6 in glomerulonephritis in vivo.
Passive immunization against TNF [23] and continuous infusion
of IL-ira [21] have shown that glomerular injury in the autologous
phase of NTN is dependent on the pro-inflammatory cytokines
TNF and IL-I. Recently, we have shown that treatment of rats
either with soluble TNF receptor (p55) or soluble IL-i type I
receptor (IL-iRtI) also ameliorates the disease activity (Alivanis,
Karkar and Rees, manuscript in preparation). Given its effects on
macrophage synthesis of IL-i, TNF and MCP-1, we expected IL-6
to reduce glomerular injury by inhibiting synthesis of pro-inflam-
matory cytokines, especially as our previous experiments in the
heterologous phase of NTN (at 4 hr), showed that IL-6 down-
regulates glomerular IL-1f3 and TNF synthesis [17], and that IL-6
reduces the ratio of IL-1f3/IL-Jra expression in glomeruli [17,
41—43]. Surprisingly, our results showed little expression of IL-lp,
IL-ira and MCP-1 at the seven day time point, which contrasts
with previous studies showing that IL-6 induces the synthesis of
IL-lra and soluble TNF receptor in vivo [15, 16]. However, the
timescale of the present experiments was very different, and the
previous studies analyzed circulating rather than glomerular con-
centrations of IL-Ira. This is consistent with our previous findings
in the autologous phase of NTN, which showed similar timing for
glomerular expression of IL-ira and IL-113. Their mRNA levels
reached maximal values four to six hours after induction of
nephritis, while concentrations detected on the fourth day were
much less [271.
The effects of IL-6 in autologous phase injury could be ex-
plained by direct effects of IL-6 on macrophage infiltration/
activation, and on the ability of macrophages to proliferate within
the inflamed glomeruli. Alternatively, IL-6 could have acted
indirectly by increasing endogenous corticosterone concentration
[44, 45]. IL-6 did increase plasma corticosterone concentrations in
our experiments, but so did the stress caused by nephritis, and
there was no difference in corticosterone levels in the IL-6 and
control nephritic groups on days I and 3. In fact, increased
concentrations were more sustained in the lL-6 treated group.
Consequently, IL-6 treated rats had less albuminuria even when
serum corticosterone concentrations were similar, which suggests
that other mechanisms are involved. The hepatic acute phase
reactant a2m reduces carrageenin-induced cutaneous inflamma-
tion and neutrophil infiltration in rats [46]. However, this does not
explain the effect of IL-6 in our experiments, since a2m concen-
trations were higher in control rats than in the IL-6 treated group,
presumably because they had more glomerular injury. Other
possibilities not addressed by our experiments include induction
of synthesis of prostaglandins [10, 37—39] and increased release of
soluble TNF receptor and IL-ira into the circulation.
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In conclusion, sustained high serum concentrations of hrIL-6
within the pathophysiological range can be obtained by continu-
ous infusion with osmotic minipumps. Such infusions attenuate all
indices of injury in the accelerated autologous phase of nephro-
toxic nephritis, even though they have a relatively small effect on
macrophage infiltration. However, treatment with IL-6 influences
the activation state of glomerular macrophages, as reflected by
surface expression of sialoadhesin and Ia molecules. These results
illustrate the potent anti-inflammatory effects of IL-6 in an active
model of nephritis in the rat, and demonstrate that manipulation
of the cytokine network could be of potential use in human
glomerulonephritis.
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APPENDIX
Abbreviations used in this article are: NTN, nephrotoxic nephritis;
GBM, glomerular basement membrane; NTS, nephrotoxic serum; hr IL-6,
human recombinant interleukin-6; IL-i j3, interleukin-1 beta; IL-ira, in-
terleukin-1 receptor antagonist; MCP- 1, monocyte chemoattractat pro-
tein-i; LPS, bacterial !ipopolysaccharide; a2m, alpha 2-macroglobulin;
PCNA, proliferating cell nuclear antigen.
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